1. Bhuiyan, M.S. and Fukunaga, K., Targeting sigma-1 receptor signaling by endogenous ligands for cardioprotection, Expert Opin. Ther. Targets, 2011, vol. 15, no. 2, p. 145.
2. Bowen, W.D., Moses, E.L., Tolentino, P.J., and Walker, J.M., Metabolites of haloperidol display preferential activity at σ receptors compared to dopamine D-2 receptors, Eur. J. Pharmacol., 1990, vol. 177, no. 3, p. 111.
3. Matsumoto, R.R. and Pouw, B., Correlation between neuroleptic binding to σ1 and σ2 receptors and acute dystonic reactions, Eur. J. Pharmacol., 2000, vol. 40, no. 2, p. 155.
4. Klouz, A., Loueslati, M.H., Daghfous, R., and Morin, D., Are sigma receptors implicated in ischemic injury? Therapie, 2001, vol. 56, no. 5, p. 557.
5. Wu, C.S., Tsai, Y.T., and Tsai, H.J., Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study, J. Am. Heart Assoc., 2015, vol. 4, no. 2, p. e001568.